1. Home
  2. SNGX vs DEVS Comparison

SNGX vs DEVS Comparison

Compare SNGX & DEVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • DEVS
  • Stock Information
  • Founded
  • SNGX 1987
  • DEVS N/A
  • Country
  • SNGX United States
  • DEVS Canada
  • Employees
  • SNGX N/A
  • DEVS N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • DEVS
  • Sector
  • SNGX Health Care
  • DEVS
  • Exchange
  • SNGX Nasdaq
  • DEVS NYSE
  • Market Cap
  • SNGX 6.5M
  • DEVS 6.1M
  • IPO Year
  • SNGX 1987
  • DEVS N/A
  • Fundamental
  • Price
  • SNGX $1.86
  • DEVS $0.53
  • Analyst Decision
  • SNGX
  • DEVS
  • Analyst Count
  • SNGX 0
  • DEVS 0
  • Target Price
  • SNGX N/A
  • DEVS N/A
  • AVG Volume (30 Days)
  • SNGX 26.0K
  • DEVS 42.7M
  • Earning Date
  • SNGX 05-09-2025
  • DEVS 05-27-2025
  • Dividend Yield
  • SNGX N/A
  • DEVS N/A
  • EPS Growth
  • SNGX N/A
  • DEVS N/A
  • EPS
  • SNGX N/A
  • DEVS N/A
  • Revenue
  • SNGX $2,342.00
  • DEVS N/A
  • Revenue This Year
  • SNGX N/A
  • DEVS N/A
  • Revenue Next Year
  • SNGX N/A
  • DEVS N/A
  • P/E Ratio
  • SNGX N/A
  • DEVS N/A
  • Revenue Growth
  • SNGX N/A
  • DEVS N/A
  • 52 Week Low
  • SNGX $1.68
  • DEVS $0.18
  • 52 Week High
  • SNGX $14.83
  • DEVS $1.91
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 38.46
  • DEVS N/A
  • Support Level
  • SNGX $1.83
  • DEVS N/A
  • Resistance Level
  • SNGX $2.00
  • DEVS N/A
  • Average True Range (ATR)
  • SNGX 0.10
  • DEVS 0.00
  • MACD
  • SNGX -0.00
  • DEVS 0.00
  • Stochastic Oscillator
  • SNGX 11.11
  • DEVS 0.00

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About DEVS DEVVSTREAM CORP

DevvStream Corp is a technology-based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve its sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.

Share on Social Networks: